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Background. Unconjugated hyperbilirubinemia results from Gilbert syndrome and from antiretroviral thera-
py (ART) containing protease inhibitors. An understanding of the interaction between genetic predisposition and
ART may help to identify individuals at highest risk for developing jaundice.
Methods. We quantified the contribution of UGT1A1*28 and ART to hyperbilirubinemia by longitudinally
modeling 1386 total bilirubin levels in 96 human immunodeficiency virus (HIV)–infected individuals during a
median of 6 years.
Results. The estimated average bilirubin level was 8.8 mmol/L (0.51 mg/dL). Atazanavir increased bilirubin
levels by 15 mmol/L (0.87 mg/dL), and indinavir increased bilirubin levels by 8 mmol/L (0.46 mg/dL). Ritonavir,
lopinavir, saquinavir, and nelfinavir had no or minimal effect on bilirubin levels. Homozygous UGT1A1*28 increased
bilirubin levels by 5.2 mmol/L (0.3 mg/dL). As a consequence, 67% of individuals homozygous for UGT1A1*28
and receiving atazanavir or indinavir had 2 episodes of hyperbilirubinemia in the jaundice range (143 mmol/L
[12.5 mg/dL]), versus 7% of those with the common allele and not receiving either of those protease inhibitors
( ). Efavirenz resulted in decreased bilirubin levels, which is consistent with the induction of UDP-glu-P ! .001
curonosyltransferase 1A1.
Conclusions. Genotyping for UGT1A1*28 before initiation of ART would identify HIV-infected individuals
at risk for hyperbilirubinemia and decrease episodes of jaundice.
Unconjugated bilirubin needs to be conjugated with
glucuronic acid to be excreted in the bile. This step
is mediated by the microsomal enzyme UDP-glucu-
ronosyltransferase (UGT). Fifteen UGT isoforms with
different substrate specificities, including the biliru-
bin-specific isoform UGT1A1, have been identified
[1]. Reduced activity of this enzyme leads to uncon-
jugated hyperbilirubinemia.
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Gilbert syndrome is the most common inherited
cause of unconjugated hyperbilirubinemia, and it oc-
curs in 3%–10% of the general population [2]. The
influence of a polymorphism in the promoter TATA
element of the gene encoding UGT1A1 has been ex-
tensively investigated in the context of Gilbert syn-
drome. Promoters containing 7 thymine adenine (TA)
nucleotide repeats, A(TA)7TAA (the UGT1A1*28 al-
lele), are less active than is the common promoter con-
taining 6 TA repeats. Thus, homozygosis for the allele
A(TA)7TAA leads to higher levels of unconjugated bil-
irubin [2–4]. The allelic frequency of this polymor-
phism differs among racial groups. It is more common
in African Americans ( ), whites (fp0.36–0.39),fp 0.43
and Indians ( ) and less common in Japanesefp 0.35
( ), Chinese ( ), and Malaysians (fp 0.11 fp 0.16 fp
) [3, 5–7]. In addition to the UGT1A1*28 allele,0.19
other polymorphisms in the UGT1A1 gene have been
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associated with Gilbert syndrome in the Japanese population
[8–10].
Unconjugated hyperbilirubinemia is also a recognized ad-
verse effect of protease inhibitor (PI) therapy containing in-
dinavir (IDV) or atazanavir (ATV) [11–13]. The pathophysi-
ological bases of this adverse effect may be the same as those
in Gilbert syndrome. Zucker et al. reported that IDV induces
hyperbilirubinemia by competitive inhibition of the UGT1A1
enzyme and found a strong association between the homozy-
gous variant allele A(TA)7TAA and the risk of developing hy-
perbilirubinemia while receiving IDV [14].
In the present study, we used a longitudinal approach to
model the influence that the UGT1A1*28 allele has on anti-
retroviral therapy (ART)–associated hyperbilirubinemia. The
aim of the study was to (1) quantify the degree of elevation in
bilirubin levels in association with various PIs, (2) assess the
interaction between the presence of the UGT1A1*28 allele and
the ART regimen, and (3) identify individuals at risk of de-
veloping jaundice after the initiation of ART.
PARTICIPANTS, MATERIALS, AND METHODS
Study participants. A total of 96 participants were recruited
from the genetics project of the Swiss HIV Cohort Study (in-
formation available at: http://www.shcs.ch). The ethics commit-
tees of all participating centers approved the genetics project, and
all participants gave written, informed consent for genetic testing.
The study population was a convenience sample as determined
by a preliminary analysis of the allelic frequency and the size of
the genetic effect. The selection criteria included having received
ATV, IDV, or lopinavir (LPV) at at least 1 time point during
follow-up. The study period was defined as the follow-up period
starting with the first study visit at which bilirubin levels were
measured (beginning in 1994) until November 2004. Total bil-
irubin and conjugated bilirubin levels were measured. The un-
conjugated bilirubin level was calculated by subtracting the con-
jugated bilirubin level from the total bilirubin level. Hyperbil-
irubinemia was graded in accordance with the AIDS Clinical
Trials Group guidelines for total bilirubin levels: grade 1 (mild),
23–32 mmol/L (1.3–1.9 mg/dL); grade 2 (moderate), 33–53mmol/
L (1.9–3.1 mg/dL); grade 3 (severe), 54–105 mmol/L (3.1–6.1 mg/
dL); and grade 4 (serious), 1105 mmol/L (16.1 mg/dL) [15].
Jaundice was defined as a total bilirubin level 143 mmol/L (12.5
mg/dL) [16].
Genetic analyses. Genomic DNA was extracted from fro-
zen peripheral blood mononuclear cells. Genotyping was per-
formed by direct sequencing by use of forward (5′-AAGTGAA-
CTCCCTGCTACCTT-3′) and reverse (5′-CCACTGGGATCA-
ACAGTATCT-3′) primers, described elsewhere [5], to generate
a product that was 253–255 bp.
Statistical analysis. The data were analyzed longitudinally
by modeling the individual effects of the different covariables
on log-transformed total bilirubin levels. We used the log trans-
formation instead of the linear scale, to stabilize variances and
obtain a more symmetric distribution. The analysis used a mul-
tivariate model proposed by Diggle [17, 18] in which the co-
variance structure arises from the consideration of 3 residual
components. This approach allows for disentanglement of the
total variation into 3 distinct dimensions: (1) a random effect
accounting for the propensity of individuals with intrinsically
high or low bilirubin levels, (2) a stationary Gaussian process
to allow for some correlation between the repeated measure-
ments from the same individual, and (3) a residual error term.
This approach is particularly relevant for cohort data, so that
an economical and plausible covariance structure can be ob-
tained. The specific advantages include the ability to accom-
modate unbalanced repeated measurements made at irregu-
lar time intervals—as is usually the case with cohort data—to
generate a flexible correlation structure with few parameters
to be estimated and thereby allowing more precise inferences,
a straightforward interpretation of regression coefficients, and
a better understanding of the sources of variability [19, 20].
Our model assumes that the covariances are stationary. How-
ever, an informal check of the assumed covariance structure as
well as of the importance of each component can be gained
by nonparametrically estimating the empirical semivariogram
[18, 21].
Covariables included in the regression model were ART reg-
imen, age, sex, hepatitis C and B serostatus, comedication (co-
trimoxazole, pyrimethamine, or rifampin), smoking status, he-
moglobin level, and the genetic factor tested. On the basis of an
initial assessment of the impact that each individual antiretro-
viral drug had on the bilirubin level in an additive multivariate
model, the ART agents were grouped as follows: (1) no ART
at the time that bilirubin level was measured, (2) ART con-
taining only nucleoside reverse-transcriptase inhibitors (NRTI
ART), (3) ART containing NRTI and nonnucleoside reverse-
transcriptase inhibitors (NNRTI ART), and ART containing
PIs (PI ART), including (4) ATV, (5) IDV, (6) LPV, (7) nelfina-
vir (NFV), (8) saquinavir (SQV), and (9) full-dose ritonavir
(RTV). For adjustment for confounding variables, cross-sec-
tional and longitudinal relationships between the continuous
explanatory variables and the response were distinguished [19,
22], and adequate functional form was assessed by use of frac-
tional polynomials [23]. Goodness of fit was evaluated by com-
paring mean observed and predicted measurements, as well as
residuals, on time plots of values in strata defined by poly-
morphisms and ART regimens. We also compared the esti-
mated variogram from our multivariate model with the non-
parametric estimate [17, 18, 21].
The analysis of interactions between genotypes and ART reg-
imens was first tested globally. If the global test was significant,
subcategories contributing to the P value were screened, and
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Table 1. Characteristics of the study participants.
Characteristic
Study
participants
Baseline age, median (IQR), years 38.3 (34.2– 46.2)
Men/women, no. (% men) 77/19 (80.2)
Ethnicity
White 92 (95.8)
African 1 (1.0)
Hispanic 3 (3.1)
Presumed HIV transmission route
Homosexual sex 43 (44.8)
Heterosexual sex 27 (28.1)
Injection drug use 23 (24.0)
Unknown 3 (3.1)
Duration of follow-up, median (IQR), years 6 (3.9–7.3)
Positive for hepatitis C antibodies 24 (25.0)
Positive for hepatitis B antigen 2 (2.1)
NOTE. Data are no. (%) of participants, unless otherwise indicated. IQR,
interquartile range.
significant and consistent strata were retained. All statistical
analyses were conducted using Stata (version 8.2 for Windows;
StataCorp) and SAS (version 8.02; SAS Institute).
RESULTS
Study participants. The UGT1A1*28 allele was present with
an allelic frequency of 0.41 and followed Hardy-Weinberg equi-
librium. The characteristics of the study participants and the
median total bilirubin levels during the follow-up period are
summarized in table 1. A total of 1386 total bilirubin and 226
unconjugated bilirubin levels were recorded during the study
period. Analyses showed a highly significant correlation between
the UGT1A1 genotype and log-transformed total and uncon-
jugated bilirubin levels ( ). These results allowed the elab-rp 0.95
oration of a longitudinal model using the log-transformed total
bilirubin level as the phenotype. The key results were thereafter
confirmed on the data set of unconjugated bilirubin levels (see
below).
The median number of measurements of total bilirubin levels
during the follow-up period was comparable in study partic-
ipants with normal (23 mmol/L [1.3 mg/dL]; mea-np 10
surements) and elevated (123 mmol/L [1.3 mg/dL]; np 15.5
measurements) total bilirubin values. Of the covariables tested,
hemoglobin levels and chronic hepatitis C or B infection were
associated with increased bilirubin levels (table 2).
Effect of ART on bilirubin levels. A total of 152 total bil-
irubin levels (11%) were measured in the absence of ART; 57
(4.1%) were measured in participants who received NRTI ART;
49 (3.5%) were measured in participants who received NNRTI
ART; and 1128 (81.4%) were measured in participants who
received PI ART that contained ATV ( ; 13.3%), IDVnp 185
( ; 38.5%), LPV ( ; 11.0%), NFV ( ;np 534 np 152 np 149
10.8%), RTV ( ; 2.3%), or SQV ( ; 5.5%). Thenp 32 np 76
median number of changes in the ART regimen per individual
was 3 (range, 1–14 changes). The influence of ART on total
bilirubin levels is shown in table 2. ATV had a stronger associa-
tion with elevated total bilirubin levels than IDV did. We eval-
uated the effect of receiving ATV or IDV alone or in combi-
nation with RTV. We did not find significant differences (P
p .30) in the estimated effect on total bilirubin levels for in-
dividuals who received ATV alone (0.38 log10 mmol/L), ATV in
combination with RTV (0.45 log10 mmol/L), IDV alone (0.27
log10 mmol/L), or IDV in combination with RTV (0.31 log10
mmol/L). The estimated average bilirubin level was 8.8 mmol/
L (0.51 mg/dL). PI ART containing ATV increased this level
by an estimated 15 mmol/L (0.87 mg/dL), and PI ART con-
taining IDV increased this level by 8 mmol/L (0.46 mg/dL).
LPV, NFV RTV, and SQV had modest effects on total biliru-
bin levels. NNRTI ART (consisting of efavirenz in 98% of the
data points) was associated with a decrease of 3.1 mmol/L
(0.18 mg/dL) in total bilirubin levels.
Effect of the UGT1A1*28 allele on bilirubin levels. The
presence of 1 or 2 copies of the variant allele resulted in a gene
dose effect on total bilirubin levels (table 2). The genetic ef-
fect was observed in the absence of treatment and across all
treatment groups (figure 1). The overall effect of homozygous
UGT1A1*28 was to increase bilirubin levels by 5.2 mmol/L (0.3
mg/dL), which was less than the increase attributed to the use
of ATV or IDV. The simultaneous presence of homozygous
UGT1A1*28 and PI ART containing ATV or IDV resulted in
nearly half of the bilirubin levels signaling grade 2 toxicity or
greater (figure 1).
Because the models were built on total bilirubin levels, we
confirmed the main findings in the restricted data set of 226
measurements of unconjugated bilirubin levels. The estimates
for the effect of treatment or genotype on unconjugated bili-
rubin levels were comparable to those obtained by using total
bilirubin levels. Compared with that in individuals who did
not receive PIs, the estimated effect on unconjugated biliru-
bin levels in individuals who received PI ART containing IDV
or ATV was an increase of 0.41 (SE, 0.07) log10 mmol/L (P !
). For PI ART containing LPV, NFV, RTV, or SQV, the effect.001
was estimated to be a decrease of 0.10 (SE, 0.084) log10 mmol/
L ( ). The estimated effect of homozygous UGT1A1*28Pp .22
on unconjugated bilirubin levels was an increase of 0.21 (SE,
0.09) log10 mmol/L ( ). The bilirubin levels reflected thePp .021
effect of the influences exerted by the antiretroviral drugs and
by the genetic background. The estimated total bilirubin level
for individuals homozygous for the UGT1A1*28 allele and who
received PI ART containing ATV was 37.7 mmol/L (2.19 mg/
dL). The global test for interactions showed only a trend for
significance ( ), and, thus, subcategories contributingPp .062
to the P value were not screened.
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Table 2. Multivariate analysis of the contribution of demographic factors, laboratory parameters, anti-
retroviral therapy, and UGT1A1 allelic variants to total bilirubin level.
Variable
Estimated (SE) effect
on total bilirubin level,
log10 mmol/L P
Referencea 0.88 …
Baseline age, per year change 0.00 (0.00) .808
Male sex 0.03 (0.04) .452
Chronic hepatitis C or B infection 0.07(0.04) .042
Longitudinal relationship between hemoglobin (per gram/dL) and bilirubin level 0.02 (0.01) .002
NRTI ART 0.06 (0.04) .127
NNRTI ART 0.20 (0.04) !.0001
PI ART
Containing ATV 0.43 (0.03) !.0001
Containing IDV 0.28 (0.02) !.0001
Containing LPV 0.06 (0.03) .031
Containing NFV 0.07 (0.03) .024
Containing RTV 0.08 (0.05) .118
Containing SQV 0.05 (0.03) .140
UGT1A1*28 heterozygous 0.07 (0.04) .072
UGT1A1*28 homozygous 0.20 (0.05) !.0001
NOTE. Values are adjusted for all the variables shown and for smoking status and comedications. For continuous variables,
the effect on the bilirubin level of each variable represents the impact of a 1-unit increase. For categorical variables, the effect
on the bilirubin level represents the impact of the indicated variable compared with the reference value. For non–log-transformed
values, refer to the text. ART, antiretroviral therapy; ATV, atazanavir; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; NNRTI, non-
nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; RTV, ritonavir;
SQV, saquinavir.
a The reference value of 0.88 log10 mmol/L (8.8 mmol/L) represents the average bilirubin level for a woman who is 38 years
old, is a nonsmoker, has the common UGT1A1 allele, does not receive ART, does not have hepatitis, and has a hemoglobin
level of 13 g/dL.
Twenty-seven participants (28%) had 2 bilirubin levels
that were 143 mmol/L (12.5 mg/dL) (the threshold for jaun-
dice). However, 6 (67%) of 9 participants homozygous for
the UGT1A1*28 allele who received ATV or IDV had bilirubin
levels in the jaundice range, versus 4 (7%) of 54 participants
with the common allele who did not receive ATV or IDV (P
! .001) (figure 1).
Overall, 183 (13.2%) of 1386 bilirubin levels were in the
jaundice range. We modeled the theoretical impact that estab-
lishing a genotyping policy before the initiation of ART would
have on jaundice. Figure 2 depicts the estimations from the
model, which show that the universal administration of PI ART
with ATV or IDV would result in 21.6% of the bilirubin levels
being in the jaundice range, whereas genotype-guided ART
would result in 5.8% of the bilirubin levels being in the jaundice
range ( ).P ! .001
DISCUSSION
We quantified the relative contribution of the UGT1A1*28 allele
and different ART combinations to hyperbilirubinemia in HIV-
infected individuals. The most relevant finding of the study is
the identification of a gene-ART association that could lead to
severe hyperbilirubinemia. Individuals with the UGT1A1*28
allele may develop jaundice when exposed to ATV or IDV. This
study was conducted primarily on a white population; howev-
er, the allele exists in other populations and is associated with
the same physiological effect, which extends the validity of the
conclusions to other ethnic groups [24].
We used an objective measurement of bilirubinemia and not
a subjective assessment of jaundice to establish the quantitative
influence of the various treatments and genotypes. Although
hyperbilirubinemia is not a serious adverse effect, clinical jaun-
dice can stigmatize the HIV-infected individual and result in
additional consultations and in treatment modification. How-
ever, because we wanted to develop a model of drug-gene in-
teraction, our goal was not primarily to assess clinical useful-
ness but, rather, to present a concept for the use of genetic da-
ta in clinics. These results extend the findings of Zucker et al.
[16] and O’Mara et al. [25], who documented an association
between the UGT1A1*28 allele and hyperbilirubinemia in in-
dividuals who receive PI ART containing IDV or ATV. A genetic
predisposition to hyperbilirubinemia has also been reported in
individuals undergoing irinotecan treatment for cancer [26].
In contrast, the use of efavirenz resulted in decreased bilirubin
levels. This observation is consistent with the known activation
by efavirenz of pregnane X receptor [27], which leads to the
induction of UGT1A isoforms [28].
The present study explored 1386 measurements of total bil-
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Figure 1. Effect of genotype and antiretroviral therapy (ART) on adjusted total bilirubin levels. Box and whisker plots (median plus interquartile
range, upper and lower adjacent values) show the distribution of total bilirubin levels according to UGT1A1 genotype. Horizontal dotted lines represent
the grades of hyperbilirubinemia (grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, serious). The gray interval corresponds to levels resulting
in jaundice (defined as 143 mmol/L). Study participants are grouped according to the no. of variant UGT1A1 alleles (white, homozygous for the common
allele; light gray, heterozygous; dark gray, homozygous for UGT1A1*28). The no. of measurements of bilirubin levels, the no. of individuals, and the
proportion of individuals who had 2 episodes of hyperbilirubinemia in the jaundice range are indicated. ATV, atazanavir; IDV, indinavir; LPV, lopinavir;
NFV, nelfinavir; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; RTV, ritonavir; SQV, saquinavir.
Figure 2. Theoretical impact of establishing a genotyping policy before the initiation of antiretroviral therapy on the proportion (95% confidence
interval) of total bilirubin levels 143 mmol/L (12.5 mg/dL), which is the threshold for jaundice.
irubin levels in 96 participants, during a median follow-up of
6 years. This allowed us to quantitate the precise influence of
multiple factors of possible relevance to bilirubin levels (ART
regimen, age, sex, hepatitis C and B serostatus, comedication,
smoking status, and hemoglobin level) against the genetic back-
ground of Gilbert syndrome. The study participants served as
their own controls through multiple changes in ART regimens
and periods when treatment was not used. We have previously
used this longitudinal modeling in the investigation of inter-
actions between apolipoprotein (APO) E and APOC3 and the
risk of severe ritonavir-associated hypertriglyceridemia [29].
The frequency of jaundice-range bilirubin levels observed un-
der various treatments and genetic backgrounds allows a pre-
liminary modeling of the potential value of introducing genet-
ic testing before the initiation of ART. We tested the scenario
“no genotyping/ATV or IDV as first-line agent” versus “geno-
type-guided ART” and narrowed the use of ATV or IDV to
individuals without the UGT1A1*28 allele. Implementation of
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such a program would lead to a theoretical 75% reduction in
the number of bilirubin levels in the jaundice range. The high
frequency of the UGT1A1*28 allele, and the high risk of de-
veloping jaundice in the setting of Gilbert syndrome when ex-
posed to specific PIs, is a good example of how genetic testing
for this allele, ideally in conjunction with testing for other
markers of toxicity, may be used in the future in the clinical
setting.
SWISS HIV COHORT STUDY TEAM MEMBERS
The members of the Swiss HIV Cohort Study are M. Battegay,
E. Bernasconi, J. Bo¨ni, H. Bucher, P. Bu¨rgisser, S. Cattacin, M.
Cavassini, R. Dubs, M. Egger, L. Elzi, P. Erb, K. Fantelli, M.
Fischer, M. Flepp, A. Fontana, P. Francioli (president), H. Furrer
(chairman of the Clinical and Laboratory Committee), M. Gor-
gievski, H. Gu¨nthard, B. Hirschel, L. Kaiser, C. Kind, T. Klim-
kait, B. Ledergerber, U. Lauper, M. Opravil, F. Paccaud, G.
Pantaleo, L. Perrin, J.-C. Piffaretti, M. Rickenbach (head of the
Data Center), C. Rudin (chairman of the Mother and Child
Substudy), P. Schmid, J. Schu¨pbach, R. Speck, A. Telenti, A.
Trkola, P. Vernazza (chairman of the Scientific Board), R. We-
ber, and S. Yerly.
Acknowledgment
We thank T. Buclin, for useful comments.
References
1. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: me-
tabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;
40:581–616.
2. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the
reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gil-
bert’s syndrome. N Engl J Med 1995; 333:1171–5.
3. Balram C, Sabapathy K, Fei G, Khoo KS, Lee EJ. Genetic polymor-
phisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a
common allele in Indians. Pharmacogenetics 2002; 12:81–3.
4. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic var-
iation in bilirubin UPD-glucuronosyltransferase gene promoter and
Gilbert’s syndrome. Lancet 1996; 347:578–81.
5. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glu-
curonosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism
for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998;
95:8170–4.
6. Biondi ML, Turri O, Dilillo D, Stival G, Guagnellini E. Contribution
of the TATA-box genotype (Gilbert syndrome) to serum bilirubin con-
centrations in the Italian population. Clin Chem 1999; 45:897–8.
7. Takeuchi K, Kobayashi Y, Tamaki S, et al. Genetic polymorphisms of
bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese
patients with Crigler-Najjar syndrome or Gilbert’s syndrome as well as
in healthy Japanese subjects. J Gastroenterol Hepatol 2004; 19:1023–8.
8. Aono S, Adachi Y, Uyama E, et al. Analysis of genes for bilirubin UDP-
glucuronosyltransferase in Gilbert’s syndrome. Lancet 1995; 345:958–9.
9. Maruo Y, Addario D, Mori A, et al. Two linked polymorphic mutations
(A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gil-
bert syndrome. Hum Genet 2004; 115:525–6.
10. Sato H, Adachi Y, Koiwai O. The genetic basis of Gilbert’s syndrome.
Lancet 1996; 347:557–8.
11. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquina-
vir hard-gel concentrations in a ritonavir-boosted once-daily regimen.
AIDS 2004; 18:1291–7.
12. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two
nucleoside analogues plus indinavir in persons with human immuno-
deficiency virus infection and CD4 cell counts of 200 per cubic millimeter
or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;
337:725–33.
13. Sulkowski MS. Drug-induced liver injury associated with antiretroviral
therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004;
38(Suppl 2):S90–S7.
14. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced
hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98:12671–6.
15. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events
associated with potent antiretroviral treatment: Swiss HIV Cohort Study.
Lancet 2001; 358:1322–7.
16. Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL.
Harrison’s principles of internal medicine. New York: McGraw-Hill,2005.
17. Diggle PJ. Analysis of longitudinal data. New York: Oxford University
Press, 2002.
18. Diggle PJ. An approach to the analysis of repeated measurements.
Biometrics 1988; 44:959–71.
19. Laird NM, Donnelly C, Ware JH. Longitudinal studies with continuous
responses. Stat Methods Med Res 1992; 1:225–47.
20. Jones RH, Boadi-Boateng F. Unequally spaced longitudinal data with
AR(1) serial correlation. Biometrics 1991; 47:161–75.
21. Diggle PJ, Verbyla AP. Nonparametric estimation of covariance struc-
ture in longitudinal data. Biometrics 1998; 54:401–15.
22. Ware JH, Dockery DW, Louis TA, Xu XP, Ferris BG Jr, Speizer FE.
Longitudinal and cross-sectional estimates of pulmonary function de-
cline in never-smoking adults. Am J Epidemiol 1990; 132:685–700.
23. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials
to model continuous risk variables in epidemiology. Int J Epidemiol
1999; 28:964–74.
24. Ioannidis JP, Ntzani EE, Trikalinos TA. “Racial” differences in genetic
effects for complex diseases. Nat Genet 2004; 36:1312–8.
25. O’Mara E, Randall D, Passarell J, et al. Population pharmacodynamic
assessment of atazanavir exposure, uridine diphosphatase-glucoronosyl
transferase (UGT) 1A1 genotype and safety in healthy human subjects
(abstract A-1253, 2002b). Program and abstracts of the 42nd Inter-
science Conference on Antimicrobial Agents and Chemotherapy (San
Diego). Washington, DC: American Society for Microbiology, 2002.
26. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with
reduced glucuronidation and increased serum bilirubin in irinotecan-
administered Japanese patients with cancer. Clin Pharmacol Ther 2004;
75:501–15.
27. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai
PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes:
comparison with rifampin and phenobarbital. J Clin Pharmacol 2004;
44:1273–81.
28. Xie W, Yeuh MF, Radominska-Pandya A, et al. Control of steroid,
heme, and carcinogen metabolism by nuclear pregnane X receptor and
constitutive androstane receptor. Proc Natl Acad Sci USA 2003; 100:
4150–5.
29. Tarr PE, Taffe P, Bleiber G, et al. Modeling the influence of APOC3,
APOE, and TNF polymorphisms on the risk of antiretroviral ther-
apy–associated lipid disorders. J Infect Dis 2005; 191:1419–26 [erratum:
J Infect Dis 2005; 191:1997].
